Japanese guidelines for adult asthma 2017.

Published on Apr 1, 2017in Allergology International4.806
· DOI :10.1016/J.ALIT.2016.12.005
Masakazu Ichinose28
Estimated H-index: 28
(Tohoku University),
Hisatoshi Sugiura33
Estimated H-index: 33
(Tohoku University)
+ 8 AuthorsKen Ohta53
Estimated H-index: 53
Abstract Adult bronchial asthma is characterized by chronic airway inflammation, and presents clinically with variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma induces airway remodeling, leading to intractable asthma. The number of patients with asthma has increased; however, the number of patients who die of asthma has decreased (1.2 per 100,000 patients in 2015). The goal of asthma treatment is to enable patients with asthma to attain normal pulmonary function and lead a normal life, without any symptoms. A good relationship between physicians and patients is indispensable for appropriate treatment. Long-term management by therapeutic agents and elimination of the causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy differentiate between mild and intensive treatments; each step includes an appropriate daily dose of an inhaled corticosteroid, varying from low to high levels. Long-acting β 2 -agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonist are recommended as add-on drugs, while anti-immunoglobulin E antibody and oral steroids are considered for the most severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled β 2 -agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by choosing treatment steps for asthma in accordance with the severity of exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-induced asthma, and pregnancy are also important issues that need to be considered in asthma therapy.
📖 Papers frequently viewed together
16 Citations
7,352 Citations
58 Citations
This study reports the results obtained with mechanical ventilation in severe respiratory failure secondary to status asthmaticus. Of the 159 patients with status asthmaticus admitted to the Intensive Respiratory Unit over a 5-yr period, 26 required mechanical ventilation for a total of 34 episodes of acute respiratory acidosis. At the time of intubation, 10 patients were in coma and 5 were in respiratory arrest. Controlled mechanical ventilation was maintained for a mean of 2.5 days. Complicati...
311 CitationsSource
#1Huib A. M. Kerstjens (UMCG: University Medical Center Groningen)H-Index: 69
#2Thomas B. Casale (USF: University of South Florida)H-Index: 75
Last. Eric D. Bateman (UCT: University of Cape Town)H-Index: 87
view all 11 authors...
Summary Background In patients with severe asthma, tiotropium improves lung function and exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting β 2 agonists. We aimed to assess the safety and efficacy of tiotropium in patients with moderate asthma who were symptomatic despite treatment with medium-dose inhaled corticosteroids. Methods We did two 24-week, replicate, randomised, double-blind, placebo-controlled, parallel-group, active-comparator trials at 233 sites in 1...
128 CitationsSource
#1Hector Ortega (GSK: GlaxoSmithKline)H-Index: 33
#2Mark C. Liu (Johns Hopkins University)H-Index: 54
Last. Pascal Chanez (AMU: Aix-Marseille University)H-Index: 86
view all 11 authors...
BackgroundSome patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids. MethodsIn this randomized, double-blind, double-dummy study, we assigned 576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high doses of inhaled glucocorticoids to one of three study groups. Patients were assigned to rece...
1,215 CitationsSource
#1Elisabeth H. Bel (UvA: University of Amsterdam)H-Index: 69
#2Sally E. Wenzel (University of Pittsburgh)H-Index: 115
Last. Ian D. PavordH-Index: 117
view all 8 authors...
Background Many patients with severe asthma require regular treatment with oral glucocorticoids despite the use of high-dose inhaled therapy. However, the regular use of systemic glucocorticoids can result in serious and often irreversible adverse effects. Mepolizumab, a humanized monoclonal antibody that binds to and inactivates interleukin-5, has been shown to reduce asthma exacerbations in patients with severe eosinophilic asthma. Methods In a randomized, double-blind trial involving 135 pati...
879 CitationsSource
#1Elisabeth H. BelH-Index: 69
#2Sally E. Wenzel (University of Pittsburgh)H-Index: 115
Last. Ian D. Pavord (University of Oxford)H-Index: 117
view all 8 authors...
Background: There is an unmet treatment need in a sub-population of severe asthma patients who, despite the use of maximal inhaled therapy, require regular treatment with oral corticosteroids (OCS). Objective: To study the steroid-sparing effect of mepolizumab in severe eosinophilic asthma. Methods: We conducted a randomized, double-blind placebo controlled trial of mepolizumab (n=69) administered as monthly injections of 100mg subcutaneously for 6 months vs placebo (n=66) in patients with sever...
11 Citations
#1Sally E. Wenzel (University of Pittsburgh)H-Index: 115
#2Linda B. FordH-Index: 8
Last. Gianluca PirozziH-Index: 31
view all 17 authors...
Background Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interleukin-4 receptor, in patients with persistent, moderate-to-severe asthma and elevated eosinophil levels. Methods We enrolled patients with persistent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microliter or a sputum eosinophil level of at least 3% who used medi...
916 CitationsSource
#1西間 三馨H-Index: 2
#3太田 國隆H-Index: 1
Last. 宮里 善次H-Index: 1
view all 27 authors...
6 CitationsSource
#1Nicola A. Hanania (BCM: Baylor College of Medicine)H-Index: 22
#2Sally E. WenzelH-Index: 115
Last. William W. BusseH-Index: 131
view all 10 authors...
Rationale: For many patients with asthma, allergic airway inflammation is primarily a Th2-weighted process; however, heterogeneity in patterns of inflammation suggests phenotypic distinctions exist that influence disease presentation and treatment effects.Objectives: To assess the potential of fractional exhaled nitric oxide (FeNO), peripheral blood eosinophil count, and serum periostin as biomarkers of Th2 inflammation and predictors of treatment effects of omalizumab.Methods: The EXTRA omalizu...
570 CitationsSource
#1Kazuto Matsunaga (Wakayama Medical University)H-Index: 24
#2Hiroki Kawabata (Wakayama Medical University)H-Index: 6
Last. Masakazu Ichinose (Tohoku University)H-Index: 28
view all 6 authors...
Abstract Combinations of inhaled corticosteroids (ICS) and inhaled long-acting beta 2 -agonists (LABA) have become widely used for the initiation of maintenance treatment for asthma. However, it has not been fully elucidated whether ICS/LABA alters the time-course of different control outcome measures in steroid-naive patients with asthma compared to the treatment with ICS alone. We compared the time-response in Asthma Control Questionnaire (ACQ), forced expiratory volume in 1 s (FEV1), exhaled ...
16 CitationsSource
#2Michael Engel (Boehringer Ingelheim)H-Index: 17
Last. Eric D. Bateman (UCT: University of Cape Town)H-Index: 87
view all 10 authors...
A b s t r ac t The patients had a mean baseline FEV 1 of 62% of the predicted value; the mean age was 53 years. At 24 weeks, the mean (±SE) change in the peak FEV 1 from baseline was greater with tiotropium than with placebo in the two trials: a difference of 86±34 ml in trial 1 (P = 0.01) and 154±32 ml in trial 2 (P<0.001). The predose (trough) FEV 1 also improved in trials 1 and 2 with tiotropium, as compared with placebo: a difference of 88±31 ml (P = 0.01) and 111±30 ml (P<0.001), respective...
480 CitationsSource
Cited By99
#1Z. Sattar (SUNY: State University of New York System)
#2Alnardo Lora (SUNY: State University of New York System)H-Index: 3
Last. Patrick Geraghty (SUNY: State University of New York System)H-Index: 2
view all 5 authors...
The S100 protein family consists of over 20 members in humans that are involved in many intracellular and extracellular processes, including proliferation, differentiation, apoptosis, Ca2+ homeostasis, energy metabolism, inflammation, tissue repair, and migration/invasion. Although there are structural similarities between each member, they are not functionally interchangeable. The S100 proteins function both as intracellular Ca2+ sensors and as extracellular factors. Dysregulated responses of m...
Background null In Japan, biologic therapy was initiated for patients with severe asthma in 2009. In recent years, four biologics with different mechanisms of action have become available in the clinical setting. However, the efficacy of switching between biologics remains uncertain. null Methods null To elucidate the efficacy of switching between biologics, 97 patients were enrolled who had received any biologic therapy for severe asthma at Jikei University Hospital, Tokyo, Japan, from July 200...
#1Haotian GaoH-Index: 1
#2Guoli WangH-Index: 1
Last. Kostya OstrikovH-Index: 69
view all 8 authors...
2 CitationsSource
#1Suguru SatoH-Index: 11
#2Junpei SaitoH-Index: 16
Last. Yoko ShibataH-Index: 37
view all 16 authors...
Background Nocturnal asthma symptoms are a well-known feature of sleep disturbance. However, there are few reports on the association between sleep-related characteristics and asthma exacerbation. The aim of the current prospective observational study was to explore the factors while sleeping associated with future asthma exacerbation. Materials and Methods At baseline, adult asthmatics underwent home sleep monitoring by a Watch-PAT instrument and then they were prospectively followed-up for the...
The global COVID-19 pandemic has brought respiratory disease to the forefront of public health, but asthma prevalence has been rising globally for decades. Asthma is mediated by errant immune activation and airway remodeling, but the influences of environment, nutrition, and comorbidities (e.g., asthma-chronic obstructive pulmonary disorder-overlap [ACO]) are still poorly understood. Even as a new generation of biologic-based treatments offer better airway control and reductions in mortality, a ...
#1Chiyo Yano (Kurume University)H-Index: 1
#2Tomotaka Kawayama (Kurume University)H-Index: 20
Last. Tomoaki Hoshino (Kurume University)H-Index: 47
view all 12 authors...
BACKGROUND Obesity is a risk factor for severe and difficult-to-treat asthma. However, the impact of different physiques on long-term outcomes is poorly understood. We aimed to investigate the correlation between obesity and asthma-associated long-term mortality in Japanese adults. METHODS From the data on 3146 individuals with air pollution-related respiratory diseases in the Omuta City Air Pollution-Related Health Damage Cohort Program, 697 adult patients with asthma were analyzed. Hazard rati...
#1Yasuo To (International University of Health and Welfare)
Last. Takashi Iwanaga (Kindai University)H-Index: 14
view all 7 authors...
Background There are limited studies on healthcare resource use (HCRU) among adult asthma patients in Japan using real-world evidence, and analysis on acute treatment and associated costs stratified by disease severity is further limited. This study aimed to characterize the disease burden of severe asthma patients in Japan in terms of HCRU and comorbid medical conditions, with particular interest in oral corticosteroid (OCS) dependency. Methods This retrospective cohort study of asthma patients...
#1Yasuhiro Gon (Nihon University)H-Index: 33
#2Naho Ohyanagi (GSK: GlaxoSmithKline)
Last. Akihiro Kobayashi (GSK: GlaxoSmithKline)H-Index: 6
view all 3 authors...
Abstract Background Poor control of asthma symptoms is associated with a higher asthma disease burden, and asthma medication adherence is a known predictor for a better control status. This study sought to describe the current asthma control status, self-reported treatment adherence, and the association between them, as well as to describe how control level and better adherence impact the health outcomes of asthma patients. Methods This study used cross-sectional data from the 2018 Japan Nationa...
#1Shujuan Luo (Boston Children's Hospital)H-Index: 1
#2Shijie Jin (Boston Children's Hospital)H-Index: 1
Last. Yanping Chen (Boston Children's Hospital)H-Index: 1
view all 7 authors...
Bronchial asthma is a chronic disease which is currently treated using various inhalants. However, the medication adherence with the inhalants is poor due to complex procedure to use them along wit...
3 CitationsSource
#1Hiromasa Inoue (Kadai: Kagoshima University)H-Index: 41
#2Ki Lee Milligan (Novartis)H-Index: 3
Last. Masakazu IchinoseH-Index: 24
view all 8 authors...
Many asthma patients remain uncontrolled despite guideline-based therapies. We examined real-life asthma control in Japanese patients prescribed with inhaled corticosteroid/long-acting β2-agonist (ICS/LABA). Patients (≥12 years) with ≥2 asthma diagnoses, newly initiated on medium-/high-dose ICS/LABA (Japanese asthma guidelines), from 01 April 2009 to 31 March 2015 were included, using Japan Medical Data Center Claims Database. Primary objective: proportion of patients with uncontrolled asthma in...